Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 9/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064708 | 0.79 | CYP1A2 (0.43) | ALDH1A1LMNACYP1A2SMN1; SMN2NOTUM | |
| SCHEMBL5061356 | 0.77 | ALDH1A1 (0.36) | ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL5065447 | 0.76 | ALDH1A1 (0.50) | ALDH1A1LMNACYP1A2TSHRHPGD | |
| SCHEMBL5061164 | 0.76 | ALDH1A1 (0.35) | ALDH1A1LMNA | |
| SCHEMBL4799770 | 0.75 | — | — | |
| SCHEMBL5458654 | 0.73 | ALDH1A1 (0.41) | ALDH1A1LMNANOTUMCSNK2A2CSNK2B | |
| SCHEMBL14032004 | 0.72 | ALDH1A1 (0.33) | ALDH1A1LMNA | |
| SCHEMBL5067504 | 0.72 | ALDH1A1 (0.40) | ALDH1A1LMNANOTUMCSNK2A2CSNK2B | |
| SCHEMBL5068984 | 0.71 | MKNK2 (0.42) | ALDH1A1LMNAHPGD | |
| SCHEMBL4800416 | 0.71 | ALDH1A1 (0.41) | ALDH1A1LMNACYP1A2TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| EP-1537112-B1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1537112-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | Astrazeneca AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004013141-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | TIE1, TEK, KDR | ALDH1A1 2177/4885LMNA 3041/4885CYP1A2 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.